pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
333
stories
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
17d
Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E
endpoints
18d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
18d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
21d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
21d
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
stat
21d
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
22d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
22d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
22d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
23d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
23d
AbCellera, Vertex partner on next-gen T-cell engagers
biopharma dive
23d
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
endpoints
23d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
23d
Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
biospace
23d
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
endpoints
23d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
23d
‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
fiercebiotech
23d
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
23d
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
23d
Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams
biospace
24d
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
24d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
← prev
page 4 of 12
next →
